Sitagliptin, a dipeptidyl peptidase-IV inhibitor, attenuates retinal neurodegeneration in rd10 mice

被引：0
|
作者：
Kutsyr, O. [1 ]
Fernandez-Sanchez, L. [2 ]
Maneu, V. [2 ]
Lax, P. [1 ]
Ambrosio, A. F. [3 ]
Cuenca, N. [1 ]
机构：
[1] Univ Alicante, Physiol Genet & Microbiol, Alicante, Spain
[2] Univ Alicante, Opt Pharmacol & Anat, Alicante, Spain
[3] Univ Coimbra, Coimbra Inst Clin & Biomed Res, Fac Med, Coimbra, Portugal
来源：
ACTA OPHTHALMOLOGICA | 2018年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
S093
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [41] TOPICAL ADMINISTRATION OF DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS PREVENTS RETINAL NEURODEGENERATION IN EXPERIMENTAL DIABETES
    Hernandez, C.
    Bogdanov, P.
    Sola-Adell, C.
    Sampedro, J.
    Simo-Servat, O.
    Garcia-Ramirez, M.
    Simo, R.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2017, 27 (03) : E113 - E113
  • [42] Topical administration of dipeptidyl peptidase IV (DPP-IV) inhibitors prevents retinal neurodegeneration in experimental diabetes
    Hernandez, Cristina
    Bogdanov, Patricia
    Sola-Adell, Cristina
    Sampedro, Joel
    Valeri, Marta
    Simo-Servat, Olga
    Herance, Raul
    Simo, Rafael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [43] PEDF deficiency increases the susceptibility of rd10 mice to retinal degeneration
    Dixit, Shivani
    Polato, Federica
    Samardzija, Marijana
    Abu-Asab, Mones
    Grimm, Christian
    Crawford, Susan E.
    Becerra, S. Patricia
    EXPERIMENTAL EYE RESEARCH, 2020, 198
  • [44] Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor on Peripheral Nerves in Streptozotocin-Induded Diabetic Rats
    Jin, Heung Yong
    Kang, Seon Mee
    Kim, Woong Ji
    Park, Ji Hyun
    Baek, Hong Sun
    Park, Tae Sun
    Kim, Chong Hwa
    DIABETES, 2009, 58 : A222 - A222
  • [45] Case History: JANUVIA™ (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
    Weber, Ann E.
    Thornberry, Nancy
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 42, 2007, 42 : 95 - 109
  • [46] Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling
    Nakamaru, Yoshinobu
    Emoto, Chie
    Shimizu, Makiko
    Yamazaki, Hiroshi
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2015, 36 (03) : 148 - 162
  • [47] Discovery of JANUVIA™ (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type2 diabetes
    Thornberry, Nancy A.
    Weber, Ann E.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (06) : 557 - 568
  • [48] Evaluation of the Antidiabetic Effects of Dipeptidyl Peptidase-IV Inhibitor ASP8497 in Streptozotocin-Nicotinamide-Induced Mildly Diabetic Mice
    Tahara, Atsuo
    Matsuyama-Yokono, Akiko
    Nakano, Ryosuke
    Someya, Yuka
    Hayakawa, Masahiko
    Shibasaki, Masayuki
    PHARMACOLOGY, 2009, 83 (03) : 177 - 187
  • [49] The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin
    Hamasaki, Hidetaka
    Yanai, Hidekatsu
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (03) : E106 - E106
  • [50] Gene expression in the brain of adult rats with behavioural alterations caused by neonatal exposure to the dipeptidyl peptidase-IV inhibitors diprotin A and sitagliptin
    Krupina, N. A.
    Zubkov, E. A.
    Orshanskaya, E. V.
    Zorkina, Y. A.
    Khlebnikova, N. N.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S173 - S173
12345